2019.03.16 (Sat) 13:00-14:40 (GMT+8)
Room 803, International Convention Center, Chang Yung-Fa Foundation
Near by MRT National Taiwan University Hospital Station, Exit2
SynCore Biotechnology Co. Ltd
Advanced Pancreatic cancer (PC) is well-known for high mortality and low survival rate. Among existing treatments and regimens, FOLFIRINOX is one of the primary and dominant regimens for clinical use. This forum invites physicians to share valuable experience in FOLFIRINOX application.
Suitable for attendees include attending physicians, residents and clinically relevant professionals.
This form is currently closed for submissions.
- The success of registration will be confirmed by phone.
- Due to quota limitation, the organizer may close the online registration at any time and retain final right of registration qualification.
- The organizer reserves the right for agenda and speaker modification due to any reasons of force majeure.